Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer [1]

European Journal of Cancer

Volumn 33, Issue 14, 1997, Pages 2435-

  Malayeri, R ^a   Wein, W ^a   Zielinski, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE;

AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; FLU LIKE SYNDROME; HUMAN; LETTER; LIVER METASTASIS; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 18544397244     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00313-4     Document Type: Article

References (5)

1. SB Kaye Gemcitabine: current status of phase I and II trials J Clin Oncol 12 1994 1527 1531
2. Carmicheal J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13 , 2731–2736.
3. M Blackstein CL Vogel Phase II study of gemcitabine in patients with metastatic breast cancer Proc Am Soc Clin Oncol 15 1996 117 135
4. M Tonato AM Mosconi C Martin Safety profile of gemcitabine Anti-Cancer Drugs 6 Suppl. 6 1995 27 32
5. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9 , 491–498.